Stay updated on Daratumumab Combo in Resistant Myeloma Clinical Trial

Sign up to get notified when there's something new on the Daratumumab Combo in Resistant Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab Combo in Resistant Myeloma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Multicentre, Open-label, Phase II study of Daratumumab and Dexamethasone in patients with resistant or refractory Multiple Myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:42.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' The new description provides examples of eligibility criteria and includes a detailed list of inclusion criteria for study participants.
    Difference
    46%
    Check dated 2024-05-22T21:26:21.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T21:58:46.000Z thumbnail image

Stay in the know with updates to Daratumumab Combo in Resistant Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo in Resistant Myeloma Clinical Trial page.